Table 1 Baseline clinical factors in patients with ALI divided between the ALI group with adverse outcome and the ALI group with no adverse outcome
Adverse Outcome | No Adverse Outcome | Total | P | |
|---|---|---|---|---|
Number of patients | 19, 65.5% | 10, 34.5% | 29 | N/A |
Age years Mean (SD) | 61 (13) | 57 (20) | 60 (14) | 0.48 |
Age years (Median) | 66 | 57 | 63 | – |
Male | 10, 52.6% | 7, 70.0% | 17, 58.6% | 0.37 |
White Race | 16, 84.2% | 10, 100.0% | 26, 89.7% | 0.19 |
Black Race | 3, 15.8% | 0, 0.0% | 3, 10.3% | 0.19 |
Genitourinary Cancer | 3, 15.8% | 3, 30.0% | 6, 20.7% | 0.38 |
Gastrointestinal Cancer | 5, 26.3% | 4, 40.0% | 9, 31.0% | 0.46 |
Gynecologic Cancer | 1, 5.2% | 0, 0.0% | 1, 3.4% | 0.47 |
Breast Cancer | 1, 5.2% | 0, 0.0% | 1, 3.4% | 0.47 |
Head and Neck Cancer | 1, 5.2% | 0, 0.0% | 1, 3.4% | 0.47 |
Thoracic (lung, mesothelioma) | 3, 15.8% | 0, 0.0% | 3, 10.3% | 0.19 |
Hematologic cancer | 1, 5.2% | 2, 20.0% | 3, 10.3% | 0.22 |
Bone/soft tissue sarcoma | 3, 15.8% | 0, 0.0% | 3, 10.3% | 0.19 |
Skin cancer | 1, 5.2% | 1, 10.0% | 2, 6.9% | 0.63 |
Stage 1 | 3, 15.8% | 4, 40.0% | 7, 24.1% | 0.16 |
Stage 2 | 2, 10.5% | 1, 10.0% | 3, 10.3% | 0.97 |
Stage 3 | 3, 15.8% | 0, 0.0% | 3, 10.3% | 0.19 |
Stage 4 | 11, 57.9% | 5, 50.0% | 16, 55.2% | 0.69 |
Active chemotherapy | 7, 36.8% | 2, 20.0% | 9, 31.0% | 0.36 |
Active prothrombotic chemotherapy | 2, 10.5% | 1, 10.0% | 3, 10.3% | 0.97 |
Active immunotherapy | 4, 21.1% | 0, 0.0% | 4, 13.8% | 0.12 |
Active radiation therapy | 2, 10.5% | 0, 0.0% | 2, 6.9% | 0.30 |
Clonal Hematopoiesis of Indeterminate Potential | 1, 5.2% | 1, 10.0% | 2, 6.9% | 0.63 |
Diabetes | 6, 31.5% | 4, 40.0% | 10, 34.5% | 0.65 |
Hypertension | 11, 57.9% | 7, 70.0% | 18, 62.1% | 0.53 |
Hyperlipidemia | 6, 31.5% | 4, 40.0% | 10, 34.5% | 0.65 |
Chronic kidney disease | 5, 26.3% | 2, 20.0% | 7, 24.1% | 0.71 |
Coronary artery disease | 7, 36.8% | 1, 10.0% | 8, 27.6% | 0.13 |
Cerebrovascular disease | 0, 0.0% | 0, 0.0% | 0, 0.0% | – |
Peripheral arterial disease | 7, 36.8% | 3, 30.0% | 10, 34.5% | 0.72 |
Obesity | 5, 26.3% | 3, 30.0% | 8, 27.6% | 0.84 |
Atrial fibrillation or other cardiac dysrhythmia | 6, 31.5% | 0, 0.0% | 6, 20.7% | 0.05 |
Smoking | 7, 36.8% | 5, 50.0% | 12, 41.4% | 0.48 |
Anti-platelet therapy | 5, 26.3% | 1, 10.0% | 6, 20.7% | 0.31 |
Statin therapy | 2, 10.5% | 2, 20.0% | 4, 13.8% | 0.49 |
Anticoagulation therapy | 3, 15.8% | 0, 0.0% | 3, 10.3% | 0.19 |
Anticoagulation indicated but held/not taken leading up to ALI | 7, 36.8% | 0, 0.0% | 7, 24.1% | 0.03 |